摘要
目的:分析40例治疗相关急性髓系白血病(t-AML)患者免疫标志跨系异常表达及其它实验室与临床特征。方法:回顾性分析2014年1月至2021年12月我院血液科40例t-AML患者的实验室和临床资料,实验室和临床资料数据通过查阅电子病历系统和实验室数据管理系统获得。采用SPSS 25.0软件进行数据分析。结果:40例患者第一肿瘤至t-AML的中位发病间隔期为21(16~41)个月;24例(60.0%)伴淋系抗原异常表达,27例(67.5%)染色体核型异常,18例(45.0%)融合基因阳性,27例(67.5%)基因突变阳性;中位RFS为11.0(1.0~79.0)个月,中位OS为11.5(1.0~80.0)个月。结论:与既往文献关于原发AML的报道相比,t-AML患者中跨系抗原表达比例高,发生基因突变的比例也高。
Objective:To analyze the abnormal expression of lymphoid antigen and other laboratory and clinical features in 40 patients with treatment-related acute myeloid leukemia(t-AML).Methods:To retrospectively analyze the laboratory and clinical data of 40 patients with t-AML in our hospital from January 2014 to December 2021.The laboratory and clinical data were obtained by consulting the electronic medical record system and laboratory data management system.SPSS 25.0 software was used for data analysis.Results:The median interval from the first tumor to t-AML in 40 patients was 21(16~41)months.24(60.0%)had abnormal expression of lymphoid antigen,27(67.5%)had abnormal karyotype,18 cases(45.0%)were positive for fusion gene,and 27 cases(67.5%)were positive for gene mutation.The median RFS was 11.0(1.0~79.0)months,and the median OS was 11.5(1.0~80.0)months.Conclusion:Compared with previous reports in the literature on primary AML,t-AML patients have a high proportion of cross-lineage antigen expression and a high proportion of gene mutations.
作者
姜艳红
焦扬
王浩
毕利军
许青霞
JIANG Yanhong;JIAO Yang;WANG Hao;BI Lijun;XU Qingxia(Department of Clinical Laboratory,the Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer Hospital,Zhengzhou KeyLaboratory of Digestive Tumor Markers,Henan Zhengzhou 450008,China;Institute of Biophysics,Chinese Academy ofScineces,Guangdong Foshan 528000,China)
出处
《现代肿瘤医学》
CAS
北大核心
2023年第16期3081-3085,共5页
Journal of Modern Oncology
基金
国家自然科学基金项目(编号:82203572)。
关键词
治疗相关
急性髓系白血病
跨系抗原表达
基因突变
treatment-related
acute myeloid leukemia
cross-lineage antigen expression
genetic mutation
